Janssen CM-strategy: A Story of Multiple Platforms From R&D to Commercial
03rd December 2020 | 10:00am CET | Jeroen Geens, Engineering Technical Director at Janssen Research & Development and Dr. Robin Meier, Manager Scientific Operations at L.B. Bohle Maschinen + Verfahren GmbH |WATCH FOR FREE
After initial CM projects and successes for specific compounds in its commercial portfolio, Janssen defined in 2015 a vision to make continuous manufacturing the default platform for the development and launch of its entire future portfolio of oral solid dosage forms.
The Janssen vision has been translated in an end-to-end CM strategy and deployment plan, across R&D and Operations, demonstrating the need to have access to different CM technology platforms in order to achieve this goal. As part of this strategy, Janssen invested in its Mirror platform, redesigned the development approach in view of Continuous Manufacturing and built external partnerships.
Important in successful deployment of the CM strategy is to continuously stick to the initial vision, despite the many challenges on the journey. While being pragmatic but selective in accepting outliers, not to be brought on CM, Janssen is shaping its CM-platform and network not only for, but mainly through the R&D-portfolio.
Presented by Jeroen Geens, Engineering Technical Director at Janssen Research & Development
Jeroen Geens holds a PhD in Chemical Engineering from Leuven University (Belgium). He joined Janssen Supply Chain in 2005 in the new technology group in SM API-manufacturing, with a focus on flow chemistry, spray drying and PAT. In 2010 he joined Janssen R&D, working in several roles in the DP Pilot Plant of Janssen’s Clinical Supply Chain, working on new product introductions for clinical manufacturing (Beerse, Belgium). In his current role of Engineering Technical Director, he works on the strategy implementation of new technologies for DP-development and manufacturing with a key focus on CM-deployment. After his initial engagement in shaping the R&D CM-platform, started 2014, he is now supporting the new product teams in bringing Janssen’s portfolio on CM-technology, while also acting as one of the lead R&D-partners for Janssen Supply Chain in the further implementation of their CM-capabilities and network strategy.
Followed by Dr. Robin Meier, Manager Scientific Operations at L.B. Bohle Maschinen + Verfahren GmbH
Dr. Robin Meier is Manager Scientific Operations at L.B. Bohle Maschinen + Verfahren GmbH and in his function responsible for the Technology Center, the QbCon®-line at L.B. Bohle and all scientific collaborations with universities and within scientific consortia. Robin is a pharmacist by education and received his doctorate in pharmaceutical technology and biopharmacy with his work on the continuous production of tablets based on twin-screw granulation. He is leading an experienced team of process- and automation engineers, who are focusing on the continuous improvement and development of the existing batch machines and the continuous manufacturing equipment.
Sponsored by L.B. Bohle Maschinen+ Verfahren GmbH
L.B. Bohle Maschinen + Verfahren GmbH is a global acting manufacturer for the pharmaceutical industry. The range of products includes process and handling equipment for the pharmaceutical solids production.
The company was founded in 1981. A large number of well-known multi nationals belong to the group of satisfied Bohle customers.
Bohle has got an export rate of about 80 %. Nearly 30 % of the total turnover is generated in the US.
Besides the batch processing technology L.B. Bohle focusses on continuous processing with the continuous production unit QbCon®.
The headquarters are in Ennigerloh, Germany, with an operating area of 40,000 m2. About 250 specialists build a highly qualified team.
Furthermore, the company is represented worlwide in about 40 countries by independent sales agencies.
The Technology Center at the headquarters was inaugurated in 2015. Bohle created the continuous production unit QbCon® together with a consortium from industry and academia. The unique feature of QbCon® is that the tablet production can be implemented either without granulation, with dry or wet granulation, in one system.
The modular concept of continuous production offers substantial time savings since it does not require any time-consuming analyses of the product samples between the process steps.